Elisha has over 25 years of drug development experience. Elisha spent the last 14 years at PPD where she was most recently Head of Development Operations. In this role, she had global accountability for a $3.5B clinical trial portfolio. Elisha also led the team who developed and executed a COVID-19 vaccine program, achieving first time in man to emergency use authorization in less than 11 months. Elisha is recognized for generating and implementing innovative, strategic solutions. She is a founding member of PPD Biotech and led the creation and implementation of an industry-leading Biotech operating model which resulted in improved project cycle times and significant business expansion. Before PPD, Elisha led the Infectious Disease and Biotech project management teams at Covance (now Labcorp Drug Development).
Scott brings over twenty years of strategic and operational experience within the pharmaceutical industry. Scott most recently served as AbbVie’s VP Scientific Affairs and Head of AbbVie Ventures. Under his leadership, the ventures group expanded its investment portfolio to include over 20 active companies. In addition, Scott served as one of AbbVie’s primary spokespersons for R&D to global media, governmental officials and investors. Previously, as VP and Head of Pharmaceutical Development, he led the global organization responsible for the development of AbbVie’s portfolio of early and late-stage clinical preregistration pipeline compounds as well as marketed compounds within therapeutic areas including oncology, neurology, immunology, renal, infectious disease and women’s/men’s health. Prior to AbbVie’s launch, Scott held positions of increasing responsibility in drug development within R&D at Abbott Laboratories. Currently Scott sits on the boards of Axial Therapeutics and Horizon and serves as a Venture Partner at Abingworth. Scott earned his MD at the Johns Hopkins University School of Medicine and completed his residency in Ophthalmology at Harvard Medical School.
Michael was Head of Product Development at Foundation Medicine from the 2016 to 2019. In this role, he led a team dedicated to the introduction of clinical and data products in the field of cancer genomics based on Next-Generation Sequencing, introducing the groundbreaking F1CDx assay as the first FDA approved and CMS reimbursed large oncology panel. Prior to this, he was Head of Regulatory Affairs at Roche Pharmaceuticals and Genentech from 2002 to 2016 overseeing the approvals of products in the field of oncology, immunology, hematology, and bone disease. During his career, he has worked in Regulatory Affairs in pharmaceutical companies based in the UK, France, Switzerland, and the US. In addition, he spent 2 years at Genentech building a new organization called Strategic Innovation which was charged with identifying and deploying disruptive concepts in the field of drug development. Today, he is a consultant and board member of several early-stage companies in both the biotech and diagnostics fields. Prior to working in the pharmaceutical industry, Michael worked at the University of Manchester, UK and Christie Hospital in the Regional Endocrinology Laboratory. He has a BSc in Biochemistry (University of Reading, UK) and a fellowship of the Institute of Medical Sciences, UK, and a Diploma in Management Studies from the University of Portsmouth, UK.
Carlos is the former CEO of Immune Design Corp., a late-stage Immunotherapy company which was acquired by Merck & Co. in April 2019. He previously served as President of Elan Pharmaceuticals and spent several years with Eli Lilly and Co. in discovery research and clinical development leadership roles, including Global Leader of the diabetes and endocrine franchise. Prior to his industry roles, Carlos spent nearly a decade at the Mayo Clinic-Rochester where his roles included Professor of Medicine, Immunology and Pathology, and Vice Dean of the clinical investigation program. Carlos is a Non-Executive Director on the boards of Mallinckrodt, Highlight Therapeutics and Fluidigm.
After receiving his medical and doctorate degrees from the Universidad Complutense of Madrid Medical School, Dr. Paya completed his specialty training in Internal Medicine, Infectious Diseases and Immunology at the Mayo Graduate School of Medicine. He was a research scientist in a post-doctoral position at Institute Pasteur in Paris and completed the advanced management program at the University of Chicago’s Booth School of Business.
Anshul has over 20 years of experience in the pharmaceutical and biotech industries as a general manager, management consultant, commercial leader and entrepreneur. Most recently, he served as Chief Commercial Officer and EVP of Peri and Post-Approval Services at PPD. He started his career at PPD as Global Head of PPD Biotech and under his leadership PPD became a market leader for CRO services in the Biotech segment. Before PPD, Anshul ran the global life sciences business unit at Gerson Lehrman Group (GLG), where he created a customer business model to serve the pharmaceutical and biotechnology industries. Prior to GLG, he worked at McKinsey, where he was an associate principal in the health care practice. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy and Opthea Ltd. (observer).
Anshul earned his B.S and M.S.E in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania.